ArticleJournal of clinical microbiology2005
Antifungal activities of tacrolimus and azole agents against the eleven currently accepted Malassezia species.
Article in Journal of clinical microbiology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 118 citations in OpenAlex.
- Treatment of facial seborrheic dermatitis with pimecrolimus cream 1%: an open-label clinical study in Korean patients.Journal of Korean medical science · 2007Trial
- Fungal Head and Neck Dermatitis: Current Understanding and Management.Clinical reviews in allergy & immunology · 2024Review
- Optimization of FK-506 production in Streptomyces tsukubaensis by modulation of Crp-mediated regulation.Applied microbiology and biotechnology · 2023Article
- Article
- The Role of the Cutaneous Mycobiome in Atopic Dermatitis.Journal of fungi (Basel, Switzerland) · 2022Review
- Review
- The Synergistic Effect of Tacrolimus (FK506) or Everolimus and Azoles AgainstFrontiers in cellular and infection microbiology · 2022Article
- In Vitro Azole and Amphotericin B Susceptibilities ofAntibiotics (Basel, Switzerland) · 2020Article
- Antifungal Resistance RegardingJournal of fungi (Basel, Switzerland) · 2020Review
- Genomic Multiplication and Drug Efflux Influence Ketoconazole Resistance inFrontiers in cellular and infection microbiology · 2020Article
- Review
- Article
- Understanding the Mechanism of Action of the Anti-Dandruff Agent Zinc Pyrithione against Malassezia restricta.Scientific reports · 2018Article
- Innate Immune and Fungal Model of Alzheimer's Disease.Journal of Alzheimer's disease reports · 2018Review
- FKBP12-Dependent Inhibition of Calcineurin Mediates Immunosuppressive Antifungal Drug Action inmBio · 2017Article
- Methodological Issues in Antifungal Susceptibility Testing of Malassezia pachydermatis.Journal of fungi (Basel, Switzerland) · 2017Review
- Article
- Efficacy and Safety of Cream Containing Climbazole/Piroctone Olamine for Facial Seborrheic Dermatitis: A Single-Center, Open-Label Split-Face Clinical Study.Annals of dermatology · 2016Article
- Azole Antifungal Sensitivity of Sterol 14α-Demethylase (CYP51) and CYP5218 from Malassezia globosa.Scientific reports · 2016Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lipophilic yeast Malassezia is an exacerbating factor in atopic dermatitis (AD) and colonizes the skin surface of patients with AD. With the goal of reducing the number of Malassezia cells, we investigated the antifungal activities of a therapeutic agent for AD, tacrolimus, and the azole agents itraconazole and ketoconazole against Malassezia species in vitro. We examined 125 strains of the 11 currently accepted Malassezia species by using the agar dilution method. All strains of the 11 Malassezia species were very susceptible to both azole agents, with MICs ranging from 0.016 to 0.25 mug/ml. Tacrolimus had antifungal activities against half of the strains, with MICs ranging from 16 to 32 mug/ml. Two of the major cutaneous floras, Malassezia globosa and Malassezia restricta, have several genotypes in the intergenic spacer region of the rRNA gene; the azole agents had slightly higher MICs for specific genotype strains of both microorganisms. A combination of azole agents and tacrolimus had a synergistic effect against Malassezia isolates, based on a fractional inhibitory index of 0.245 to 0.378. Our results provide the basis for testing these agents in future clinical trials to reduce the number of Malassezia cells colonizing the skin surface in patients with AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.